Kornimate/medical-research-clean huggingface dataset:
transplant patient registry of liver, kidney and/or pancreas

Conditions: End Stage Renal Disease; End Stage Liver Disease

Summary: this is a registry of data collected from patient records, both of those who have a condition which may require transplantation and those who have undergone transplantation of the liver, kidney and/or pancreas.

honest broker arrangement.

Eligibility criteria:
inclusion criteria: * patients followed in the transplant clinic at virginia commonwealth university health system

Keywords: transplant transplantation of liver, kidney, pancreas
angiotensin receptor blockers and angiotensin-converting enzyme inhibitors and adverse outcomes in patients with covid19

Conditions: Corona Virus Infection; COVID-19

Summary: suspension of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors and adverse outcomes in hospitalized patients with coronavirus infection.

several interactions by pre-existing therapies for chronic diseases, therapies used by sars-cov2 infection generate doubts about risks and benefits. among these situations in which the current data indicate a situation of equipoise would be about the maintenance or suspension of acei / bra in patients with sars-cov2 infection. increasing the expression of eca-2 could increase the binding to the virus, however, there are studies that indicate this increase in eca-2 could be protective. so far, there is no clinical evidence to confirm any of the theories, and this question can only be clarified through a randomized clinical trial. the objective is to evaluate the impact of the suspension of the use of angiotensin-converting enzyme (ace) inhibitors and angiotensin receptor blockers (bra) on the length of hospital stay and on the mortality of patients with sars-cov2 infection.

Eligibility criteria:
inclusion criteria: * patients hospitalized with covid-19 diagnosis using ace inhibitors or blockers of angiotensin receptor; * patients ≥ 18 years old; * maximum use of 3 antihypertensive drugs; * sign the consent form. exclusion criteria: * severe evolution with orotracheal intubation, use of mechanical ventilation and / or hemodynamic instability in the first 24 hours until covid-19 diagnosis confirmation; * patients hospitalized per decompensated congestive heart failure in the last 12 months; * use of sacubitril/valsartan * pregnancy * recent acute renal failure and shock

Keywords: blockers of angiotensin receptor angiotensin-converting enzyme inhibitors sars-cov2
effect of ugir in adults with compromised gut function and malabsorption

Conditions: Irritable Bowel Syndrome; Crohn Disease; Ulcerative Colitis; Celiac Disease

Summary: this study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.

this prospective, non-randomized, open-label study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption. adults with irritable bowel syndrome (ibs), inflammatory bowel disease (ibd) or celiac disease were enrolled in the study and asked to take the study product for 6 weeks. the primary measure of the study was a validated quality of life questionnaire, the gastrointestinal quality of life index (giqli). secondary measures included the inflammatory bowel disease questionnaire (ibdq), the celiac disease questionnaire (cdq), and the digestive symptom frequency questionnaire (dsfq).

Eligibility criteria:
inclusion criteria: * body mass index 19 - 40 kg/m2 * previous diagnosis of ulcerative colitis (uc), crohn's disease, irritable bowel syndrome (ibs), or celiac disease exclusion criteria: * gastroenterologic surgery within 3 months before the study period * have a colostomy or ileostomy bag * malignancy within the last 5 years * women who are lactating, pregnant or planning pregnancy during the study period * taking antibiotic, antiparasitic, or antifungal medications * initiation of or changes to supplements or medications within 28 days prior to screening
prospective non-randomized evaluation of oncoplastic surgery

Conditions: Breast Image Scale Index for Self Esteem Evaluation; Breast Symmetry Index; Quality of Life; Morbidity; Oncological Outcome

Summary: breast conserving therapy (bct) is the standard treatment for intraductal or invasive breast cancer patients. however cosmetic results, e.g. symmetry and nipple displacement, are sometimes poor reducing the quality of life. the use of immediate techniques for oncoplastic surgery (itop) seems to improve subjective cosmetic outcome. oncologic safety of itop has been demonstrated by several authors using restrospective analyses. however, no prospective observational trial has been done to objectively evaluate cosmetic and oncologic outcome comparing bct with itop. the aim of this study is to investigate this issue within a prospective non randomized observational trial at the medical university vienna.


Eligibility criteria:
inclusion criteria: * patients scheduled for unilateral breast conserving surgery due to cancer or a suspicious lesion, in whom \>10%\* of breast volume (measured by mammograms using a defined formular 37) has to be removed or breast cancer patients scheduled for mastectomy and immediate reconstruction (immediate or delayed contralateral correction is allowed) * birads iv, v or vi are eligible * \> 18 years of age * psychological and physical capable of understanding and performing the trial * signed written informed consent \* if oncologic safety necessitates to resect more than half of one breast quadrant exclusion criteria: * inflammatory breast cancer * progression after neoadjuvant therapy * pregnant women * patients unable to perform surgery under general anaesthesia * bilateral breast lesions
safety and effectiveness of bms-986263 in adults with compensated cirrhosis (liver disease) from nonalcoholic steatohepatitis (nash)

Conditions: Nonalcoholic Steatohepatitis (NASH)

Summary: the purpose of this randomized study is to assess safety and effectiveness of bms-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (nash).


Eligibility criteria:
inclusion criteria: * participants with liver biopsy fibrosis score stage 4 (nash crn) performed within 12 months * men and women must agree to follow methods of contraception exclusion criteria: * worsening liver disease or any disease might compromise participant safety in the opinion of the investigator * known immunocompromised status or any disease or condition which might compromise participant safety * prior exposure to bms-986263 * clinically relevant abnormal physical examination, vital signs, ecg, or clinical laboratory tests * hepatic decompensation other protocol-defined inclusion/exclusion criteria apply

Keywords: nonalcoholic steatohepatitis liver disease nash compensated cirrhosis
clinical decision unit (cdu) - evaluation of a novel approach to address emergency department overcrowding

Conditions: Acute Illness

Summary: this randomized controlled trial will introduce a clinical decision unit (cdu) into the university of alberta hospital emergency department(ed)and assess the influence on ed length of stay, patients who leave without being seen, and other ed overcrowding outcomes.

the study will take place over a 6-week period that will be spilt into three-two-week blocks. using computerized blocks of 2 weeks, days of the week will be randomly allocated so that each day of the week receives one intervention (cdu) and one control day for the study period. the cdu involves transforming an ed bed location to a 6-chair internal waiting room with 2 adjacent beds assigned to act as assessment and treatment locations. patients will transition between the chair and stretcher to optimize the use of ed space.

Eligibility criteria:
inclusion criteria: * only adult patients (\>17 years of age) presenting to the university of alberta hospital emergency department (uah ed), during the study interval will be included in the evaluation. exclusion criteria: * direct admits/pediatric patients.

Keywords: emergency department, administration, overcrowding
hypoglycemia counterregulation and symptom perception with insulin detemir

Conditions: Diabetes Mellitus; Hypoglycemia

Summary: hypoglycemia and unawareness of hypoglycemia are major problems of insulin therapy in patients with diabetes mellitus. the long acting insulin analogue detemir has structural and physicochemical properties which differ from human insulin. the aim of the present study is to test whether this leads to altered hormone and symptom response during hypoglycemia.


Eligibility criteria:
inclusion criteria: * healthy subjects male or female * age 18-50 years * female subjects save contraception * ability to take part in the study * signed consent exclusion criteria: * chronic disease * acute disease during 4 weeks prior to the study * pregnancy * drug treatment other than hormonal contraception

Keywords: counterregulation hypoglycemia unawareness insulin therapy
on dose efficiency of modern ct-scanners in chest scans

Conditions: Pneumonia; Lung Cancer; Pulmonary Embolism; Pulmonary Disease; Aortic Stenosis

Summary: ct scans of the chest / thorax are of great importance both in the initial diagnosis and in the follow-up of pulmonary or thoracic diseases. as an example, ct angiography of the pulmonary arteries (ctpa) is worldwide considered to be gold standard test in patients with a suspicion for pulmonary embolism. the aim of this study is to measure and compare dose efficiency of modern ct scanners for unenhanced and contrast-enhanced scan protocols of the chest/thorax. patients who are referred for a ct of the chest/thorax will be randomly assigned to one of the three ct scanners currently in use at our institution.


Eligibility criteria:
inclusion criteria: * patient is referred for an unenhanced ct or contrast-enhanced ct of the chest/thorax confirmed by a board-certified radiologist ('justifying indication' according to german/european radiation protection law) and * patient is at least 18 years of age and * patient (is able to give informed consent and) has given informed consent. exclusion criteria: * high degree of medical urgency (i.e. patient cannot be consented for iv contrast according to routine procedures) * known or suspected pregnancy, or lactating . contraindications for contrast agent (renal failure, allergy, hyperthyroidism)

Keywords: spectral ct computed tomography dose efficiency
effect of stretching on visco-elastic behaviour of the fascia plantaris in a healthy population

Conditions: Fasciitis, Plantar; Stretch; Rehabilitation; Stiffness of Unspecified Foot, Not Elsewhere Classified

Summary: rct with two arms: (1) stretch fascia plantaris (6 weeks, n=30) (2) control (n=30); outcome parameters: rom ankle and first toe; visco-elastic behaviour of the fascia plantaris determined by means of myotonometry study protocol: outcome parameters were evaluated before and after the intervention/control with a 6 weeks interval. all participants were screened bilaterally and for the participants assigned to the intervention group stretching was only performed on the dominant side


Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * lower extremity injury
duloxetine combined with intra-articular injection of corticosteroid and hyaluronic acid reduces pain in the treatment of knee osteoarthritis patients

Conditions: Osteoarthritis, Knee; Chronic Pain

Summary: intra-articular injection of corticosteroid and hyaluronic acid is a common treatment for osteoarthritis of the knee. as a treatment drug for patients with depression, duloxetine has been shown in many studies to effectively relieve the pain of osteoarthritis and improve the function of the knee joint. however, there is no evidence regarding the efficacy of intra-articular injection of corticosteroid and hyaluronic acid combined with duloxetine for pain management in patients with knee osteoarthritis. the aim of the study was to test the hypothesis that intra-articular injection of corticosteroid plus hyaluronic acid combined with duloxetine could achieve superior pain management effects to intra-articular injection of corticosteroid plus hyaluronic acid alone in patients undergoing knee osteoarthritis pain.


Eligibility criteria:
inclusion criteria: * participants meet american college of rheumatology clinical and radiographic criteria for the diagnosis of knee osteoarthritis with knee pain \[ pain for ≥14 days of each month for ≥3 months before study entry, with a mean score ≥4 on the 24-h average pain score (0-10) using the average of daily ratings before the trial\] * body mass index \< 40 kg/m2 * radiographic criteria included kellgren-lawrence grade ⅱ-iii * knee stability, no deformity, no lumbar spondylosis with radiculopathy. * good cognition, and the ability to understand the study protocol and the agreement to participate. exclusion criteria: * inflammatory arthritis, autoimmune disorder, septic arthritis, or any other concomitant disease (such as liver and kidney disease) * those who prior synovial ﬂuid analysis indicative of a diagnosis other than osteoarthritis * participants with contraindications to duloxetine (currently using monoamine oxidase inhibitors, poorly controlled angle-closure glaucoma), previous exposure to duloxetine, combined with other drugs acting on the central nervous system (such as benzodiazepines) and allergic to any of the medications used in this study. * with metabolic diseases or anticoagulation therapy * participants who had received invasive treatments to the knee during the past 6 months; joint replacement of the knee at any time or current infection in the affected limb.

Keywords: osteoarthritis, knee chronic pain hyaluronic acid corticosteroid duloxetine intra-articular injection
gaming technology to encourage healthy weight and activity in youth

Conditions: Childhood Obesity

Summary: the goal of the proposed randomized controlled trial is to test the efficacy of exergaming (i.e. video gaming that involves physical activity) to reduce adiposity in overweight and obese children.

the gamesquad study is a 6-month, 2-arm randomized controlled trial among 46 overweight/obese children (aged 10 to 12 years) assigned to: 1) 3 hours/week of in-home exergaming or 2) a control group. an innovative aspect is the inclusion of a fitness trainer who will regularly video chat with the participant and virtually monitor gameplay. the study will advance the field by: 1) establishing the efficacy of exergaming to reduce bmiz among overweight and obese children and 2) demonstrating the potential of exergaming to reduce body fat and improve children's cardiovascular health.

Eligibility criteria:
inclusion criteria: * bmi percentile \> or equal to 85 on the cdc growth chart * participating household has a high-speed internet connection * at least 1 family member or friend who is willing to exergame in the home with the participant for 3 hours/week exclusion criteria: * pregnant * impairments that prevent normal ambulation * previous history, or current symptoms of, cardiovascular disease, musculoskeletal injury, or epileptic seizures

Keywords: bmiz exergaming cardiovascular disease
study to assess the prognostic value of the antithrombin iii in the acute pancreatitis (at-propanc)

Conditions: Acute Pancreatitis

Summary: this is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin iii in the development of moderate or severe acute pancreatitis.

this is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin iii in the development of moderate or severe acute pancreatitis. in the context of clinical practice of general surgery and apparatus digestive services, patients entering with mild acute pancreatitis will be asked to participate in the study and if so, they will sign the informed consent. on admission, demographic and anthropometric data of the patient will be recorded, as well as medical history, patient's admission data and vital signs. patient's blood will be drawn for analysys and the risk of organ failure will be measured by modified marshall and apache ii scales. the assessments and procedures performed are the standard practice at the center. at 24 hours (± 3 hours) and at 7 days (or nine days to avoid weekends) after admisison, vital signs will be recorded, laboratory tests will be performed and the risk of organ failure will be measured by modified marshall and apache ii scales. at discharge of the patient (regardless of when it occurs), the outcome of the acute pancreatitis will be recorded. . those patients discharged within the first month after admission will be visited or called (according to standard practice at the center) one month after arrival, to record follow-up data, including health condition, readmissions and abdominal pain evaluation by visual analog scale.

Eligibility criteria:
inclusion criteria: * patients diagnosed with mild acute pancreatitis according to seriousness criteria established by banks et al, 2013. * patients of either sex aged ≥ 18 years . * patients who have given their written informed consent exclusion criteria: * patients with exacerbated chronic pancreatitis. * patients with coagulation disorders (congenital and acquired antithrombin deficiency) . * patients with liver cirrhosis. * pregnant patients

Keywords: acute pancreatitis
safety and efficacy study of 2 pancreatic enzymes for treatment of exocrine pancreatic insufficiency in cystic fibrosis.

Conditions: Exocrine Pancreatic Insufficiency: Cystic Fibrosis

Summary: the purpose of the study is to further evaluate the safety and efficacy of eur-1008 as compared to kreon® in the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis in subjects 12 years of age and older.


Eligibility criteria:
inclusion criteria: 1. definitive diagnosis of cf based on the following: * one clinical feature consistent with cf and * either a genotype with 2 identifiable mutations known to cause cf or a sweat chloride concentration \>60 meq/l by pilocarpine iontophoresis 2. pancreatic insufficiency documented by a monoclonal faecal elastase (fe) 100 μg/g stool at screening (test results within the previous 12 months are acceptable) 3. currently receiving pancreatic enzyme replacement therapy 4. adequate nutritional status based on the following: body mass index (bmi) \>19 kg/m2 in adult subjects or a bmi percentile 10th percentile for age in adolescent (12 to 17 years age group) subjects 5. are clinically stable with no evidence of concomitant illness or acute upper or lower respiratory tract infection that requires antibiotics during the 7-day interval prior to screening and preceding entry into this clinical study exclusion criteria: 1. age \<12 years 2. known contraindication, hypersensitivity, or intolerance to pork or other porcine peps 3. current uncontrolled diabetes mellitus 4. history of solid organ transplantation 5. history of surgery affecting the bowel function and weight gain

Keywords: exocrine pancreatic insufficiency cystic fibrosis pancreatic insufficiency
rectal indomethacin versus rectal indomethacin and sublingual nitrate for pep prevention

Conditions: Post-ERCP Acute Pancreatitis

Summary: patients undergoing endoscopic retrograde cholangiopancreatography (ercp) are at risk for post-ercp pancreatitis (pep), which is associated with adverse outcomes. combination prophylaxis strategies are increasingly investigated to prevent pep more effectively, and studies have confirmed the benefits. two randomized controlled trials revealed that combination prophylaxis with rectal nsaids and sublingual nitrate has reduced pep rates to 5.6%-6.7% in average-risk patients. however, there was concern regarding the safety of sublingual nitrate with reports of significant increasing the risk of hypotesion (rate of 54.9%) and headache (rate of 4.1%) as compared with placebo. as a safety drug, rectal administration of one dose nsaids is recommended as basic chemoprophylaxis in common or high-risk patients in guidelines. results from previous studies showed rectal administration of nsaids significantly reduced pep rate to 4-5.3% in average-risk patients. although the difference in demographics, study design and outcomes definition, evidence was obtained that rectal nsaids was associated with similar pep rate as combination prophylaxis with rectal nsaids and sublingual nitrate. however, evidence is lacking from large, randomized clinical trials indicating that efficiency of pep prevention with rectal nsaids alone is not inferior to with combination prophylaxis. the investigators conduct this trial to investigate the hypothesis that rectal nsaids alone is non-inferior to the combination prophylaxis in terms of pep prevention, but with reduce side effect.


Eligibility criteria:
inclusion criteria: * patients (age, 18-80 y) with native papilla planned for diagnostic or therapeutic ercp were eligible for enrollment in the study. exclusion criteria: * contraindications to ercp; * allergy to nitrates or nsaids; * currently on nitrate medication; * receiving nsaids within 7 days; * not suitable for indomethacin eg, gastrointestinal hemorrhage within the past 4 weeks, renal dysfunction (creatinine level \>1.4 mg/dl) or the presence of coagulopathy before the procedure (international normalized ratio \> 1.5); * acute pancreatitis within 3 days; * pregnant or breastfeeding women; * unwilling or inability to provide consent.

Keywords: ercp post-ercp pancreatitis pep nsaids indomethacin nitrate